The use of tyrosine kinase inhibitors (TKIs) that target BCR-ABL is a well-established and highly effective strategy for sustained disease control in chronic myeloid leukemia (CML). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.